2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-111164
    CBS-3595 908380-97-2 98%
    CBS-3595 is a dual inhibitor of p38 MAP kinase and phosphodiesterase 4 with anti-inflammatory and anti-allodynic activities. CBS-3595 reduces the production of the proinflammatory cytokine IL-6 and increases the levels of the anti-inflammatory cytokine IL-10 in rats. CBS-3595 reduces paw oedema formation in the Complete Freund’s adjuvant (CFA) (HY-153808)-induced arthritis rat model. CBS-3595 is promising for research of autoimmune diseases.
    CBS-3595
  • HY-111167
    AN-2898 906673-33-4 98%
    AN-2898 is a selective PDE4 inhibitor with IC50 of 0.027 μM over other phosphodiesterase enzymes, such as PDE1A, PDE2A and PDE3A. AN-2898 also potently inhibits PDE4 subtypes (PDE4B1, PDE4A1A and PDE4D2). AN-2898 significantly inhibits the production of TNF-α, IL-2, IFN-γ, IL-5 and IL-10. AN-2898 can be used for mild to moderate atopic dermatitis (AD) and psoriasis research.
    AN-2898
  • HY-111198
    YM-355179 fumarate 887647-69-0 98%
    YM-355179 fumarate is a newly synthesized selective CCR3 antagonist with the potential to inhibit eosinophil-related allergic inflammatory diseases. YM-355179 can effectively inhibit the binding of CCL11 and CCL5 to CCR3-expressing cells, with IC50 values of 7.6 nM and 24 nM respectively. In functional experiments, YM-355179 can inhibit CCL11-induced intracellular Ca(2+) influx, chemotaxis and eosinophil degranulation, IC50 The values are 8.0 nM, 24 nM and 29 nM respectively.
    YM-355179 fumarate
  • HY-111214
    K-14585 880546-17-8 98%
    K-14585 is a peptide competitive PAR2 antagonist. K-14585 inhibits PAR2-dependent IL-8 production, NF-κB phosphorylation, and p38 signaling. K-14585 reduces SLIGKV (PAR2 agonist peptide)-induced Ca2+ mobilisation in primary human keratinocytes.
    K-14585
  • HY-111258
    GSK345931A 869499-38-7 98%
    GSK345931A is an EP1 receptor antagonist. GSK345931A shows measurable CNS penetration in the mouse and rat and potent analgesic efficacy in acute and sub-chronic models of inflammatory pain.
    GSK345931A
  • HY-111274
    Indomethacin farnesil 85801-02-1
    Indomethacin farnesil is an orally active proagent of Indomethacin. Indomethacin (Indometacin) is a potent, blood-brain permeable and nonselective inhibitor of COX1 and COX2, with IC50s of 18 nM and 26 nM for human COX-1 and COX-2, respectively, in CHO cells. Indomethacin disrupts autophagic flux by disturbing the normal functioning of lysosomes.
    Indomethacin farnesil
  • HY-111304
    MF266-1 848188-18-1 98%
    MF266-1 is a selective E prostanoid receptor 1 (EP1) antagonist with an Ki value of 3.8 nM. MF266-1 also has moderate selectivity for thromboxane A2 receptor (TP). MF266-1 is promising for research of arthritis.
    MF266-1
  • HY-111366
    CD12681 1952239-59-6 98%
    CD12681 (compound 14) is a potent and selective RORγ inverse agonist with IC50 of 19 nM and 10 nM for RORγ GAL4 and CD4-IL-17 cells, respectively. CD12681 decreases the IL-17 inflammatory cell recruitment. CD12681 has the potential for the research of psoriasis.
    CD12681
  • HY-111392
    Glucametacine 52443-21-7 98%
    Glucametacine is an anti-inflammatory agent.
    Glucametacine
  • HY-111515
    BAY-678 racemate 675103-35-2 98.30%
    BAY-678 racemate is a racemate of BAY-678. BAY-678 is an orally bioavailable, highly potent, selective and cell-permeable inhibitor of human neutrophil elastase (HNE), with an IC50 of 20 nM. BAY-678 is also nominated as a chemical probe to the public via the Structural Genomics Consortium (SGC).
    BAY-678 racemate
  • HY-111947
    c-Fms-IN-6 1628574-81-1 98%
    c-Fms-IN-6 is a potent inhibitor of c-FMS, with an IC50 of ≤10 nM for unphosphorylated c-FMS, also weakly inhibits unphosphorylated c-KIT and PDGFR (IC50, > 1 μM). Used in the research of autoimmune diseases.
    c-Fms-IN-6
  • HY-111948
    c-Fms-IN-7 1313408-89-7 98%
    c-Fms-IN-7 is a cFMS inhibitor extracted from patent WO2011079076A1, example159, has an IC50 of 18.5 nM.
    c-Fms-IN-7
  • HY-111950
    (-)-Ibuprofenamide 121839-78-9 98%
    (-)-Ibuprofenamide is an amide proagent of Ibuprofen with anti-inflammatory activity. Ibuprofen is an anti-inflammatory inhibitor targeting COX-1 and COX-2 with IC50s of 13 μM and 370 μM, respectively.
    (-)-Ibuprofenamide
  • HY-111970
    SAR113945 869796-50-9 98%
    SAR113945 (compound 1) is a highly potent IKK-β inhibitor with an IC50 of 0.4 nM. SAR113945 is used for research on inflammatory and cancerous diseases.
    SAR113945
  • HY-111996
    Kv3 activator-1 1380696-64-9 99.41%
    Kv3 activator-1 is a Kv3 family voltage-gated potassium channel activator. Kv3 activator-1 reverses mechanical hyperalgesia in rat models of neuropathic and inflammatory pain, with rapid onset and long-lasting, dose-related effects. Kv3 activator-1 can be used for the research of pain.
    Kv3 activator-1
  • HY-112042
    Aspirin Trelamine 7194-12-9 98%
    Aspirin Trelamine is a salicylic acid prodrug. Aspirin Trelamine has been used in research related to ischemic stroke, as well as COVID-19-associated acute respiratory distress syndrome (ARDS) and pneumonia.
    Aspirin Trelamine
  • HY-112219
    H3R antagonist 1 1448422-61-4 99.21%
    H3R antagonist 1 is a histamine receptor 3 (H3R) inverse agonist. H3R antagonist 1 increases the expression levels of myelin-associated glycoprotein (MAG) and myeline basic protein (MBP) in differentiating oligodendrocytes. H3R antagonist 1 can be used for the study of multiple sclerosis.
    H3R antagonist 1
  • HY-112265
    CRTh2 antagonist 1 1379445-54-1 98%
    CRTh2 antagonist 1 is a CRTh2 antagonist with an IC50 of 89 nM.
    CRTh2 antagonist 1
  • HY-112363
    Aloisine A 496864-16-5 98%
    Aloisine A (RP107) is a a potent cyclin-dependent kinase (CDK) inhibitor with IC50s of 0.15 μM, 0.12 μM, 0.4 μM, 0.16 μM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK5/p35, respectively. Aloisine A ininhibits GSK-3α (IC50=0.5 μM) and GSK-3β (IC50=1.5 μM). Aloisine A stimulates wild-type CFTR and mutated CFTR, with submicromolar affinity by a cAMP-independent mechanism. Aloisine A has the potential for CFTR-related diseases, including cystic fibrosis research.
    Aloisine A
  • HY-112369
    LDDN-0003499 331662-51-2 98%
    LDDN-0003499 is a Src family tyrosine kinase inhibitor and anti-inflammatory agent. LDDN-0003499 reduces basal and Aβ-stimulated levels of active, phosphorylated Lyn and Src kinases, and attenuates Aβ-stimulated secretion of pro-inflammatory cytokines TNFα and IL-6 in microglial cells. LDDN-0003499 can be used for the research of Alzheimer's disease.
    LDDN-0003499
Cat. No. Product Name / Synonyms Application Reactivity